Top

Published in:

01-03-2010 | Letter to the Editor

High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis

Authors: Yuki Kagoya, Akira Hangaishi, Tsuyoshi Takahashi, Yoichi Imai, Mineo Kurokawa

Published in: International Journal of Hematology | Issue 2/2010

Excerpt

Immune thrombocytopenic purpura (ITP) is a hematologic disorder characterized by autoimmune-mediated platelet destruction. Although prednisone (or prednisolone) is generally used for treatment of ITP, high-dose dexamethasone therapy is also effective and leads to rapid recovery of platelet count [1]. In contrast, optimal management of secondary ITP has not been well established. Here, we present a case of significant thrombocytopenia and neutropenia accompanied with Epstein–Barr virus (EBV)-induced infectious mononucleosis (IM). …

Godeau B, Bierling P. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831–6.CrossRef

Hess RD. Routine Epstein–Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42:3381–7.CrossRefPubMed

Pipp ML, Means ND, Sixbey JW, Morris KL, Gue CL, Baddour LM. Acute Epstein–Barr virus infection complicated by severe thrombocytopenia. Clin Infect Dis. 1997;25:1237–9.CrossRefPubMed

Hammond WP, Harlan JM, Steinberg SE. Severe neutropenia in infectious mononucleosis. West J Med. 1979;131:92–7.PubMed

Cyran EM, Rowe JM, Bloom RE. Intravenous gammaglobulin treatment for immune thrombocytopenia associated with infectious mononucleosis. Am J Hematol. 1991;38:124–9.CrossRefPubMed

Takahashi T, Hamasaka N, Harada S, Sugawara N, Yoshimoto M. Methylprednisolone pulse therapy for severe immune thrombocytopenia associated with infectious mononucleosis. Am J Hematol. 2007;82:416–7.CrossRefPubMed

Title: High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis
Authors: Yuki Kagoya
Akira Hangaishi
Tsuyoshi Takahashi
Yoichi Imai
Mineo Kurokawa
Publication date: 01-03-2010
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0485-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Non-cirrhotic extrahepatic portal vein thrombosis: a 6-year long case history

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group

Incidence of koilonychia and atrophy of the lingual papillae in a patient with iron-deficiency anemia

Chest nodule in a patient with multiple myeloma

Monitoring plasma heparin concentration in a patient with antiphospholipid syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer